div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: · Pfizer Limited Fachinformation IBRANCE @ 75100125 mg Hartkapseln November 2016 1 2017-03-01 Nutzenbewertung-lQWiG Palbociclib-D-264-2pdf 2 Weide R Feiten S Friesenhahn src=https:reader034fdocumentsinreader034viewer20220502135f5f814c66419b68952d7fd2html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: · Pfizer Limited Fachinformation IBRANCE @ 75100125 mg Hartkapseln November 2016 1 2017-03-01 Nutzenbewertung-lQWiG Palbociclib-D-264-2pdf 2 Weide R Feiten S Friesenhahn src=https:reader034fdocumentsinreader034viewer20220502135f5f814c66419b68952d7fd2html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: · Pfizer Limited Fachinformation IBRANCE @ 75100125 mg Hartkapseln November 2016 1 2017-03-01 Nutzenbewertung-lQWiG Palbociclib-D-264-2pdf 2 Weide R Feiten S Friesenhahn src=https:reader034fdocumentsinreader034viewer20220502135f5f814c66419b68952d7fd2html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: · Pfizer Limited Fachinformation IBRANCE @ 75100125 mg Hartkapseln November 2016 1 2017-03-01 Nutzenbewertung-lQWiG Palbociclib-D-264-2pdf 2 Weide R Feiten S Friesenhahn src=https:reader034fdocumentsinreader034viewer20220502135f5f814c66419b68952d7fd2html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: · Pfizer Limited Fachinformation IBRANCE @ 75100125 mg Hartkapseln November 2016 1 2017-03-01 Nutzenbewertung-lQWiG Palbociclib-D-264-2pdf 2 Weide R Feiten S Friesenhahn...